Oculogenex is developing a gene therapy targeting the degeneration of central vision in patients with dry macular degeneration, utilizing precise genetic modifications to restore retinal function. This therapy aims to provide a treatment option for patients suffering from blinding retinal diseases, significantly enhancing their quality of life.
Funding
$1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Dry macular degeneration leads to the progressive loss of central vision, significantly impacting the quality of life for affected individuals, and currently lacks effective treatment options. Many patients experience irreversible vision loss due to the degeneration of the retinal pigment epithelium (RPE) and subsequent photoreceptor damage.
Solution
Oculogenex is developing a novel gene therapy designed to halt the progression of dry macular degeneration by targeting the underlying genetic factors that contribute to RPE cell dysfunction. The investigational therapy aims to restore retinal function and prevent further vision loss through precise genetic modifications delivered directly to the affected cells. By addressing the root cause of the disease, Oculogenex seeks to provide a long-term solution that preserves central vision and improves the daily lives of patients with dry macular degeneration. The therapy is currently undergoing preclinical evaluation, including a research study on the International Space Station.
Target Audience
The primary target audience includes patients diagnosed with dry macular degeneration who are experiencing progressive vision loss and have limited treatment options.
Features
- AAV-based gene therapy vector for targeted delivery to RPE cells
- Designed to address specific genetic mutations associated with dry macular degeneration
- Intravitreal injection for direct administration to the retina
- Proprietary formulation to enhance gene transfer efficiency and minimize off-target effects
- Preclinical studies demonstrating improved RPE cell function and photoreceptor survival